Baricitinib in the Setting of Second-Line Therapy for Rheumatoid Arthritis: A US-Based Budget Impact Model from a Commercial Healthcare Payer Perspective

Document Type

Presentation

Loading...

Media is loading
 

Publication Date

7-24-2024

Comments

Presentation: 16:32

Abstract

Rheumatoid arthritis (RA) is a disease that afflicts around 20% of the adult population in the United States (US), primarily the elderly. Financially, the RA market accounts for over $650,000,000 in gross revenue world-wide. This market has a compound annual growth rate of 5.4% and is projected to continue to lead the US in chronic health conditions both clinically and financially. Treatment for RA can range from a variety of therapies and include costs anywhere between $50,000-$150,000 per year. Given the large financial and clinical burdens of RA, this capstone aimed at developing a budget impact model (BIM) to assess the impact of adding baricitinib, a novel therapy, into a commercial healthcare payer formulary. Model inputs, including prevalent population, market drug shares with and without intervention, discontinuation rates, and drug costs were collected from peer-reviewed literature and assumptions about the model were made when necessary. Results of the model found that adding baricitinib to a formulary could potentially save healthcare payers over $2,000,000 within the 5-year time horizon. Furthermore, associated costs of baricitinib were found to be lower than those of leading market drugs. A one-way sensitivity analysis was conducted to determine impactful variables to the model. Results of the analysis concluded that the variance in the eligible patient population lead to the largest difference in budget impact between the upper and lower boundaries of the analysis. In conclusion, there is evidence to suggest that baricitinib is a clinically effective drug that can substantially decrease the RA drug budget of a commercial healthcare payer. Further economic evaluations should be conducted to add evidence in support of this claim.

Language

English

This document is currently not available here.

Submit Feedback on Presentation

Share

COinS